ImmuCell (NASDAQ: ICCC) is one of 25 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare ImmuCell to related companies based on the strength of its earnings, valuation, profitability, analyst recommendations, risk, institutional ownership and dividends.
This table compares ImmuCell and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares ImmuCell and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ImmuCell||$13.72 million||-$1.30 million||-26.21|
|ImmuCell Competitors||$408.45 million||-$6.78 million||119.28|
ImmuCell’s rivals have higher revenue, but lower earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
14.0% of ImmuCell shares are held by institutional investors. Comparatively, 54.6% of shares of all “Diagnostic substances” companies are held by institutional investors. 13.9% of ImmuCell shares are held by company insiders. Comparatively, 8.1% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
ImmuCell has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, ImmuCell’s rivals have a beta of 1.77, indicating that their average share price is 77% more volatile than the S&P 500.
This is a breakdown of current recommendations for ImmuCell and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ImmuCell currently has a consensus price target of $14.00, suggesting a potential upside of 181.12%. As a group, “Diagnostic substances” companies have a potential downside of 4.84%. Given ImmuCell’s stronger consensus rating and higher probable upside, analysts plainly believe ImmuCell is more favorable than its rivals.
ImmuCell beats its rivals on 8 of the 13 factors compared.
ImmuCell Company Profile
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.